Our Pricing

Understanding Omeprazole Interactions

Published on: June 03, 2026

Understanding omeprazole interactions weight loss medications UK is essential for safe, effective treatment. Omeprazole, a proton pump inhibitor (PPI) commonly prescribed for acid reflux and gastro-oesophageal reflux disease (GORD), is used by millions of UK patients—many of whom also seek weight loss treatments. At Cured Pharmacy, our UK-registered clinical team assesses all medication interactions during your free online consultation to ensure your treatment plan is safe and optimised for your individual needs.

How Omeprazole Works and Why Interactions Matter

Omeprazole belongs to the proton pump inhibitor (PPI) class and works by reducing stomach acid production, providing relief from conditions like GORD, peptic ulcers, and dyspepsia [1]. It achieves this by irreversibly blocking the hydrogen-potassium ATPase enzyme system in gastric parietal cells, which is the final step in acid secretion.

Because omeprazole alters gastric pH and is metabolised primarily via the cytochrome P450 enzyme system (specifically CYP2C19 and CYP3A4), it has the potential to interact with other medications [1]. These interactions can affect drug absorption, metabolism, and overall efficacy. For patients considering weight loss treatments alongside omeprazole, understanding these mechanisms is crucial for safe prescribing.

The MHRA advises that all patients disclose their complete medication history—including over-the-counter treatments like omeprazole—during clinical assessments to identify potential drug interactions early [2].

Omeprazole Interactions with GLP-1 Weight Loss Injections

GLP-1 receptor agonists, including tirzepatide (Mounjaro), semaglutide (Wegovy), and liraglutide (Saxenda), work by mimicking the incretin hormone GLP-1, which regulates appetite, slows gastric emptying, and improves glycaemic control [3]. These injectable treatments are licensed by the MHRA for weight management in adults with a BMI of 30 kg/m² or above, or 27 kg/m² with weight-related comorbidities.

Current evidence suggests no significant pharmacokinetic interaction between omeprazole and GLP-1 receptor agonists [3][4]. Because GLP-1 medications are administered subcutaneously and do not rely on gastric absorption, changes in stomach pH caused by omeprazole do not affect their bioavailability. Additionally, GLP-1 agonists are not metabolised via cytochrome P450 pathways, eliminating the risk of enzyme-mediated interactions.

However, both omeprazole and GLP-1 treatments can cause gastrointestinal side effects—nausea, bloating, and abdominal discomfort are common, particularly during the initial titration phase of GLP-1 therapy [3]. Patients taking both medications may experience additive GI symptoms, which should be monitored by a UK prescriber. In the STEP trials for semaglutide, up to 44% of participants reported mild to moderate nausea, typically resolving within the first few weeks [4].

Clinical Considerations for Combined Use

UK prescribers at Cured Pharmacy assess your full medical history, including current PPI use, to determine whether GLP-1 weight loss treatments are appropriate. While omeprazole does not contraindicate GLP-1 therapy, patients with pre-existing GORD or gastric conditions may require closer monitoring during dose escalation. Your prescriber may recommend starting at the lowest available dose and titrating gradually to minimise gastrointestinal discomfort.

Omeprazole and Orlistat: Important Absorption Considerations

Orlistat, marketed as Xenical, Alli, and generic orlistat, is a lipase inhibitor that reduces dietary fat absorption by approximately 30% [5]. Unlike GLP-1 injections, orlistat is taken orally and works locally in the gastrointestinal tract, meaning it does not undergo systemic metabolism via cytochrome P450 enzymes.

There is no direct pharmacokinetic interaction between omeprazole and orlistat [5]. However, orlistat can interfere with the absorption of fat-soluble vitamins (A, D, E, and K), and patients are typically advised to take a multivitamin supplement at least two hours before or after orlistat. Omeprazole, particularly with long-term use, has been associated with reduced absorption of certain nutrients, including vitamin B12, magnesium, and calcium [1][2].

Patients taking both medications should be monitored for potential cumulative nutritional deficiencies. A UK prescriber may recommend periodic blood tests to assess micronutrient levels, particularly in those using omeprazole for extended periods exceeding 12 months.

Omeprazole Interactions with Mysimba (Naltrexone/Bupropion)

Mysimba is a combination weight loss medication containing naltrexone (an opioid antagonist) and bupropion (a norepinephrine-dopamine reuptake inhibitor) [6]. Bupropion is extensively metabolised by the cytochrome P450 enzyme CYP2B6, with minor involvement of CYP2C19—the same enzyme inhibited by omeprazole [1][6].

While omeprazole primarily inhibits CYP2C19 and CYP3A4, the interaction with bupropion is generally considered clinically insignificant, as CYP2C19 plays only a minor role in bupropion metabolism [6]. However, omeprazole may slightly increase plasma concentrations of bupropion or its active metabolites in some individuals, particularly those who are CYP2C19 poor metabolisers.

UK prescribers will assess your metabolic profile and medication history before prescribing Mysimba alongside omeprazole. Patients should be monitored for potential CNS side effects such as headache, dizziness, or insomnia, which are common with Mysimba and may be exacerbated by altered bupropion metabolism [6].

When to Inform Your Prescriber

Always disclose omeprazole use—whether prescribed or purchased over-the-counter—during your online consultation at Cured Pharmacy. Our UK-registered prescribers will evaluate your complete medication list, including dose and duration of PPI therapy, to ensure safe prescribing of weight loss treatments. If you experience new or worsening side effects after starting combined therapy, contact your prescriber immediately.

Managing Omeprazole Interactions: Practical Guidance for UK Patients

Most patients taking omeprazole can safely use weight loss medications, provided they are under the supervision of a UK-registered prescriber. At Cured Pharmacy, your free online consultation includes a comprehensive medication review to identify potential interactions before treatment begins.

For patients prescribed GLP-1 injections like Mounjaro or Wegovy alongside omeprazole, the key consideration is managing overlapping gastrointestinal side effects. Starting at the lowest dose and titrating slowly—as recommended in NICE guidelines—can minimise nausea and improve tolerability [7]. Taking omeprazole consistently at the same time each day, typically 30 minutes before breakfast, optimises its efficacy and reduces breakthrough acid symptoms.

Patients using orlistat should ensure adequate spacing between orlistat doses and any fat-soluble vitamin supplements, and discuss long-term PPI use with their prescriber to assess nutritional status. Those prescribed Mysimba should report any unusual CNS symptoms promptly, as these may indicate altered drug metabolism.

When to Seek Further Advice

Contact your prescriber if you experience severe or persistent side effects, including uncontrolled nausea, vomiting, abdominal pain, or signs of nutrient deficiency such as fatigue, muscle weakness, or tingling. Cured Pharmacy's clinical team is available to review your treatment plan and adjust dosing as needed to ensure safe, effective weight loss therapy.

Why Choose Cured Pharmacy for Weight Loss Treatment with Omeprazole

Cured Pharmacy is a UK-registered online pharmacy (GPhC Registration Number 9012511) with a dedicated clinical team led by Superintendent Pharmacist Tarun Kumar (GPhC 2233073). We provide transparent upfront pricing, with weight loss treatments starting from competitive rates, and all prices are displayed before your consultation—no hidden fees or unexpected charges.

Our free online consultation takes under three minutes and is reviewed by UK-registered prescribers who assess your full medication history, including omeprazole and other PPIs. We dispense only genuine UK-licensed medicines, delivered discreetly to your door with next-day options available. Whether you're considering GLP-1 injections, orlistat, or Mysimba, our team ensures your treatment plan is safe, effective, and tailored to your individual needs.

All prescription medications require clinical assessment by a UK prescriber. Start your free consultation today by selecting your preferred weight loss treatment and completing the online questionnaire. Our clinical team will review your submission and, if approved, arrange discreet delivery to your chosen address.

Scientific References

1. Strand, D. S., Kim, D., & Peura, D. A. (2017). 25 Years of Proton Pump Inhibitors: A Comprehensive Review. Gut and Liver, 11(1), 27–37. https://doi.org/10.5009/gnl15502 [accessed 13 August 2026]
2. Medicines and Healthcare products Regulatory Agency. (2012). Proton pump inhibitors in long-term use: reports of hypomagnesaemia. Drug Safety Update, 5(11), A1. https://www.gov.uk/drug-safety-update/proton-pump-inhibitors-in-long-term-use-reports-of-hypomagnesaemia [accessed 13 August 2026]
3. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
4. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
5. Torgerson, J. S., Hauptman, J., Boldrin, M. N., & Sjöström, L. (2004). XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care, 27(1), 155–161. https://doi.org/10.2337/diacare.27.1.155 [accessed 13 August 2026]
6. Greenway, F. L., Fujioka, K., Plodkowski, R. A., et al. (2010). Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet, 376(9741), 595–605. https://doi.org/10.1016/S0140-6736(10)60888-4 [accessed 13 August 2026]
7. National Institute for Health and Care Excellence. (2023). Semaglutide for managing overweight and obesity. Technology appraisal guidance [TA875]. https://www.nice.org.uk/guidance/ta875 [accessed 13 August 2026]
8. NHS. (2026). Heartburn and acid reflux. https://www.nhs.uk/conditions/heartburn-and-acid-reflux/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication or combining treatments with existing prescriptions such as omeprazole.